See every side of every news story
Published loading...Updated

Revelation completes patient dosing in study of Gemini in CKC - BioTuesdays

Summary
Revelation Biosciences (NASDAQ: REVB) has announced the completion of dosing for its PRIME Phase 1b study of escalating doses of intravenously administered Gemini—a proprietary formulation of phosphorylated hexaacyl disaccharide—in patients with stage III and stage IV chronic kidney disease (CKC). According to Revelation, several study data sets are expected during Q3, 2025, including safety standards, changes in hematologic parameters, in vitro evaluation, and multiple biomarkers of activity. In a statement, James Rolke, CEO of Revelation, commented, “We thank our investigator and participants for the rapid completion of dosing. We are looking forward to sharing the study data shortly, and engaging the FDA to discuss future clinical development and approval pathways later this year.” The post Revelation completes patient dosing in study of Gemini in CKC appeared first on BioTuesdays.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

biotuesdays.com broke the news in on Thursday, July 17, 2025.
Sources are mostly out of (0)